Ashok V, Yun K, Klebanoff M, Kaufman E, Aysola J, Richmond T Characteristics Associated with Community Violence Prevention Programs in US Hospitals: A Cross-Sectional Survey Analysis. , Academic Emergency Medicine.: 2026 (Under Revision)

Klebanoff MJ, Lin JC, Long JA, Doshi JA Medicare Part D Appeals of Denied Prescriptions for Glucagon-like Peptide-1 Receptor Agonists, 2020-2025. , SGIM Annual Meeting.: 2026 (Accepted Poster Presentation)

Doshi JA, Klebanoff MJ, Merchant M, Li P, Kazi DS Trends in Utilization, Spending, and Coverage for PCSK9 Inhibitors in Medicare Part D. , American College of Cardiology Annual Scientific Session.: 2026 (Accepted Poster Presentation)

Klebanoff MJ, Li P, Long JA, Doshi JA Medicare Part D Coverage and Costs for Glucagon-Like Peptide-1 Receptor Agonists. , JAMA., 334(20): 2025,1848-1850

Klebanoff MJ, Chetty AK, Doshi JA Medicaid Coverage and Prior Authorization for Antiobesity Glucagon-Like Peptide-1 Receptor Agonists: A Cross-Sectional Study of State Policies. , J Gen Intern Med.: 2025,(Online ahead of print)

Li P, Lin JK, Klebanoff MJ, Palkar R, Chahin S, Doshi JA Reducing the Out-of-Pocket Costs of Disease-Modifying Therapies for Medicare Beneficiaries With Multiple Sclerosis. , Neurol Clin Pract., 15(6): 2025,e200536

Doshi JA, Li P, Klebanoff MJ, Lin JK Inflation Reduction Act Provisions and Medicare Part D Out-of-Pocket Costs for Specialty Drugs. , JAMA Health Forum., 6(5): 2025

Klebanoff MJ, Chetty AK, Doshi JA Prior Authorization Policies for Antiobesity GLP-1 Agonists across State Medicaid Programs. , Society of General Internal Medicine Annual Meeting.: 2025

Klebanoff MJ, Li P, JA Long, Doshi JA Trends in Medicare Part D Formulary Coverage, Prior Authorization, and Out-of-Pocket Costs for Glucagon-like Peptide-1 Receptor Agonists, 2020-2025. , AcademyHealth Annual Research Meeting (Podium Presentation).: 2025

Klebanoff MJ, Li P, Chatterjee P, Doshi JA Real-time Prescription Benefit Tool Adoption Among U.S. Hospitals. , JAMA Health Forum., 5(10): 2024,e243181